Clinical trials: Stage III Prostate Cancer AJCC v8
Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer
This phase II trial evaluates the best duration for relugolix to be given in combination with radiation therapy when treating patients with high risk prostate cancer. Prostate cancer is a hormonal influenced cancer.
- Conditions
- Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT06129851
- Testing
- Biospecimen Collection, Bone Scan, Brachytherapy
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Kansas Medical Center
Prostate Cancer
SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer
RATIONALE: SB939 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well SB939 works in treating patients with recurrent or metastatic prostate…
- Trial name
- NCT01075308
- Testing
- HDAC inhibitor SB939
- Where
- 7 sites in Canada
- Volunteers
- 32 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for the treatment of men with prostate cancer who are starting long-term ADT for the first time, termed hormone-naïve prostate cancer.
- Trial name
- STAMPEDE (NCT00268476)
- Testing
- Celecoxib, Docetaxel, Prednisolone
- Where
- 120 sites in Switzerland, United Kingdom
- Volunteers
- 11,992 people
- Sponsor
- Medical Research Council